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OBJECTIVES: The Chronic Care Model (CCM) is a framework for enhancing health
care delivery for chronic illnesses through six elements: self-management support,
delivery system design, community resources, organizational support, decision
support, and clinical information systems. The CCM was implemented at USAF
Wilford Hall Medical Center from 2006 through 2008, but little is known about its
long-term effectiveness. METHODS: We used the ARCHeS interface to the Archi-
medes model to forecast the effectiveness of the CCM compared to the current
levels of care in the US (CLC) over 20 years for patients with type 2 diabetes. We
modeled the CCM intervention effects on health outcomes and disease progression
of diabetes based on empirical biomarker change results from three-year military-
based clinical data. The primary analysis focused on the effectiveness in terms of
diabetes related health outcomes, while a secondary analysis considered cost-
effectiveness from a health care system perspective. RESULTS: Compared with
CLC, the relative reductions in 20-year Kaplan-Meier incidence due to the CCM
were 10.3%, 3.8%, 5.8%, 6.0%, 11.1% for myocardial infarction, proliferative diabetic
retinopathy, blindness, foot ulcer, and foot amputation, respectively. The CCM
resulted in a 6.7% relative reduction in coronary heart disease death, and a 0.6%
relative reduction in all-cause death. The CCM had no compelling benefits for
reducing the incidence of stroke or nephropathy. CONCLUSIONS: We found the
CCM lowers the risk of morbidity and mortality from diabetes in a military popu-
lation. Our results using ARCHeS simulations are broadly consistent with previous
Markov model studies but extend those results by providing a more detailed un-
derstanding of the specific health outcomes affected by the CCM, as well as the
impact on comorbidities associated with diabetes.
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OBJECTIVES: Type 2 Diabetes Mellitus (TTDM) contributes to the body’s inability to
produce a sufficient amount of insulin in order to sustain glucose levels necessary
for energy production. The study aim is to determine the association between
multiple diet therapies and the clinical profile of adult patients with TTDM.
METHODS: We conducted a mixed-treatment comparison meta-analysis of ran-
domized diet therapies for TTDM patients. Therapies included high carbohydrate
and isocaloric (HCI); high carbohydrate and hypocaloric (HCH); low carbohydrate
and isocaloric (LCI); and low carbohydrate and hypocaloric (LCH). A systematic
literature search was conducted through December 2010. The primary outcomes
measured were hemoglobin A1c (HbA1c), high-density lipoprotein (HDL) choles-
terol, low-density lipoprotein (LDL) cholesterol, and triglycerides. These outcomes
were dichotomized based upon American Diabetes Association (ADA) standards. A
diet was considered successful if the patient’s HbA1c was 7%, HDL was 40
mg/dL, LDL was 100 mg/dL, or triglycerides were 150 mg/dL. Mixed-treatment
comparison meta-analysis was used to combine direct, within-trial, and between-
trial comparisons with indirect trial evidence from other trials while maintaining
randomization. Results are reported as odds ratios (OR) and 95% credible intervals
(CI). RESULTS: In total, 10 studies (21 treatment arms and 340 patients) were in-
cluded in the analysis. For bothHbA1c and triglycerides, theHCHdiet yielded lower
measurements compared to the HCI diet (OR: 0.89 CI: 0.04, 20.86; OR: 0.58 CI: 0.02,
15.55, respectively for HbA1c and triglycerides) and LCI diet (OR: 0.47 CI: 0.02, 7.45;
OR: 0.15 CI: 0.001, 6.28, respectively for HbA1c and triglycerides). LDL and HDL
cholesterol measurements were not found to be statistically significantly different
among the four diet types. CONCLUSIONS: This study illustrated no statistically
significant differences existed between the four types of diets with respect to four
clinical outcomes. Further research is necessary to identify an optimal diet combi-
nation for patients with TTDM.
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OBJECTIVES: To compare the effect of antihyperglycemic FDCs on A1C and adher-
ence relative to CDTs in clinical practice.METHODS: A 2-part systematic literature
review and meta-analysis were performed to compare the A1C response and ad-
herence between the 2 drug regimens. Inclusion criteria limited articles to studies
that compared equivalent drug components within FDC and CDT. Searches used
Medline, Embase, and Cochrane databases. Of the 1246 identified abstracts, 152
articles were reviewed, and 8met the inclusion criteria. Results were extracted and
pooled in a meta-analysis, using a random-effects model. Unreported standard
deviations were imputed according to the Cochrane Handbook. Cohort compari-
sons were described as mean differences (MD) with 95% confidence intervals (CIs).
RESULTS:A total of 37,173 patients comprised the 16 reported cohort comparisons.
Five comparisons described A1C reductions in FDC and CDT cohorts, and a meta-
analysis revealed a greater reduction in A1C with FDC (MD, 0.5% [95% CI: 0.8,
0.3%]). Eleven comparisons evaluated medication adherence (measured by med-
ication possession ratio [MPR]) between the FDC and CDT cohorts. These 11 cohort
comparisons were divided into 3 subgroups due to different study designs. Five
comparisons described MPR for FDC and CDT cohorts, with higher adherence with
FDC (MD, 12% [95% CI: 5, 19%]). Three comparisons examined patients who
switched from monotherapy to FDC or CDT, with higher adherence for patients
who switched to FDC (MD 8% [95%CI: 6, 10%]). Three comparisons described results
for patients who switched from CDT to FDC or stayed on CDT, with higher adher-
ence for patients who switched to FDC (MD 5% [95% CI, 3, 7%]). CONCLUSIONS:Use
of antihyperglycemic FDCs was associated with lower A1C levels and higher MPRs
compared to CDT in patients with T2DM in clinical practice.
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OBJECTIVES: The Objective of this research is to compare health care costs and
medication persistence for patients initiating treatment using exenatide, pen in-
sulin or vial insulin. METHODS: Commercial health plan data [2004 to 2008] were
used to identify episodes of anti-diabetic drug therapy which were then classified
according to treatment history: first observed treatment; restarting a previous ther-
apy [90-day gap in all treatment]; switching therapy; and augmentation therapy.
All exenatide and insulin episodes were selected for this analysis. Multivariate
statisticalmethods adjusted for demographics, drug use history, priormedical care
use, comorbidmedical conditions, and prescription drug profile. Several sensitivity
analyses were conducted. RESULTS: 213,701 episodes of anti-diabetic drug therapy
were identified of which 7,031 patients initiated using exenatide, 21,011 used vial
insulin [VI] and 422 used pen insulin [PI]. Time to all cause discontinuation [TTAD]
wasmeasured for the index drug and all diabetic-related drugs. Pen insulin [PI] was
discontinued 91 days earlier than exenatide [p0.0001], while vial insulin [VI] was
continued 18 days longer than exenatide [p0.01]. PI patients discontinued all
anti-diabetic drugs 34 days earlier than exenatide patients [p0.05] while ex-
enatide andVI patients exhibited similar TTAD for all drugs. Relative to vial insulin,
exenatide use was estimated to reduce first-year medical costs by $4,629
[p0.0001] which was sufficient to offset higher prescription drug costs for ex-
enatide [$519, p0.0001]. Similar cost results were found comparing exenatide to
pen insulin but were not statistically significant, likely due to the limited sample
size for pen insulin. These results were confirmed using propensity scorematching
estimation andwere robust across episode type.CONCLUSIONS: Patients initiating
drug therapy using exenatide incur lower post-treatment costs than similar pa-
tients who initiated treatment using insulin.
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OBJECTIVES: The Potential for Benefit conceptual model is a framework to identify
subgroups of patients with differential potential for response to treatment. Within
this context, we developed the ENSEMBLE Minimum Dataset (MDS), a collection of
patient reported measures, to assess patient heterogeneity. The objective of this
research is to provide evidence that ENSEMBLE MDSmeasures can be used to form
subgroups that are clinically and statisticallymeaningful in their ability to discrim-
inate proxies for treatment response. METHODS: A cross-sectional survey was
mailed to 3380 type 2 diabetes patients identified from a large administrative
claims database. ENSEMBLE MDS measures included: Total Illness Burden Index
(TIBI), EQ-5D, Psychological Health Questionnaire (PHQ-4), Perceived Stress Scale
(PSS-4), Perceived Social Support (MOS-SS), MacArthur Scale of Subjective Social
Status (M-SSS), MacArthur Income Question (MIQ), Barrett Simplified Measure of
Social Status (BSMSS), Self-reported Depression (DQ), and Self-Reported Health
(SRH). Proxies for treatment response were patient global impression of disease
severity (PGIS), patient global impression of improvement (PGII) and overall disease
burden. We assessed the ability of ENSEMBLE MDS measures to discriminate
among levels of PGIS, PGII, and burden via unadjusted, adjusted, and trend
analyses. RESULTS: A total of 724 patients responded with complete survey data
and were categorized into 3 levels on PGIS, PGII, and burden. TIBI, EQ-5D, PHQ-4,
PSS-4, MOS-SS, andM-SSS discriminated across the levels of PGIS, PGII, and burden
(p  0.05) for all analyses. DQ discriminated burden for all analyses (p  0.01) and
PGII and PGIS for unadjusted and trend analyses (p  0.05). BSMSS only showed
significant trend for burden (p 0.05).CONCLUSIONS: Results of this study provide
evidence that the componentmeasures of the ENSEMBLEMDSdiscriminate among
levels of disease severity, improvement, and burden. Future research includes test-
ing these measures in other disease areas, testing alternative patient reported
measures, and creating a composite scoring algorithm.
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OBJECTIVES: To compare the multivariable-adjusted logistic regression model
with the propensity score-matched, propensity score-stratified, and propensity
score-adjusted logistic regression models in estimating the effect of exposure to
antidepressant agents in increasing the risk of type 2 diabetesmellitus.METHODS:
A retrospective cohort study using the Texas Medicaid prescription claims data-
basewas conducted from January 1, 2002 to December 31, 2009. Patients aged 18-64
years with new prescriptions for antidepressants (exposed group) or benzodiaz-
epines (unexposed group) and without diabetes at cohort entry were included in
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